Healthcare >> Analyst Interviews >> October 14, 2002
FARIBA F. GHODSIAN is currently Managing Director and Director of
Healthcare Research at Roth Capital Partners, where she provides
coverage of the biotechnology industry and is involved in public and
private financing for biotechnology companies. She has been an active
member of the financial and scientific communities for over 15 years,
having held positions of Scientist, Director of Business Development,
acting Chief Financial Officer, and Board member for privately and
publicly held biotechnology and pharmaceutical companies, such as
Allergan, MedClone, and Trega Biosciences. Most recently, she worked as
Vice President and Senior Biotechnology Analyst for several investment-
banking firms, such as Lehman Brothers, Hancock Institutional (Sutro and
Tucker Anthony) and Wedbush Morgan Securities. Dr. Ghodsian is a well-
published author, holds several patents, and has served on the
Scientific Grant Review Board of the National Institutes of Health. She
has also been a frequent guest speaker in investment and industry
conferences and on television programs about biotechnology industry
trends and investments. Dr. Ghodsian is a founding Board member of the
Southern California Biomedical Council and serves on the Board of
Trustees of the American Technion Society. Dr. Ghodsian received her MBA
from UCLA (Beta Gamma Sigma), postdoctoral fellowship from Harvard
Medical School, PhD in Biomedical Engineering from Oxford University, MS
in Chemical Engineering from MIT, and BS in Chemical Engineering from
Technion, Israel Institute of Technology. Profile
from a funding point of view?
Dr. Ghodsian: From a funding point of view, we have actually had very
strong years, and this
